Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Goodwill (2016 - 2025)

Historic Goodwill for Ligand Pharmaceuticals (LGND) over the last 16 years, with Q3 2025 value amounting to $101.5 million.

  • Ligand Pharmaceuticals' Goodwill fell 352.4% to $101.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $101.5 million, marking a year-over-year decrease of 352.4%. This contributed to the annual value of $105.2 million for FY2024, which is 181.87% up from last year.
  • Ligand Pharmaceuticals' Goodwill amounted to $101.5 million in Q3 2025, which was down 352.4% from $101.5 million recorded in Q2 2025.
  • Ligand Pharmaceuticals' 5-year Goodwill high stood at $190.5 million for Q2 2021, and its period low was $3.7 million during Q3 2023.
  • Moreover, its 5-year median value for Goodwill was $105.2 million (2024), whereas its average is $118.9 million.
  • In the last 5 years, Ligand Pharmaceuticals' Goodwill tumbled by 4451.88% in 2022 and then soared by 273769.21% in 2024.
  • Over the past 5 years, Ligand Pharmaceuticals' Goodwill (Quarter) stood at $190.2 million in 2021, then dropped by 4.72% to $181.2 million in 2022, then plummeted by 42.95% to $103.4 million in 2023, then increased by 1.82% to $105.2 million in 2024, then decreased by 3.52% to $101.5 million in 2025.
  • Its last three reported values are $101.5 million in Q3 2025, $101.5 million for Q2 2025, and $101.5 million during Q1 2025.